Evaluation of Patients Treated With Omalizumab (Anti-Ige) During The Pandemic Period

Authors : Zuhal KARALI, Şükrü ÇEKİÇ, Öner ÖZDEMİR, Yakup CANITEZ, Nihat SAPAN

Pages : 118-125

Doi:10.12956/tchd.1116584

View : 44 | Download : 11

Publication Date : 2023-03-22

Article Type : Research Paper

Abstract :Objective: There are few studies investigating the impact of the COVID-19 pandemic on patients using omalizumab. In this study, it was aimed to investigate the effects of the COVID-19 pandemic on our patients who have been treating with omalizumab. Material and Methods: From two centers, a total of 20 patients participated in the study. A questionnaire, consisting of 45 questions prepared by our department, and a visual analogue scale insert ignore into journalissuearticles values(0: minimum, 10: maximum); were applied face-to-face to the patients. Results: It was observed that six patients insert ignore into journalissuearticles values(30%); did not continue their omalizumab treatment during the pandemic period. While 90% insert ignore into journalissuearticles values(n=18); of the patients were wearing masks, 85% insert ignore into journalissuearticles values(n=17); stated that they paid attention to social distance. In our study, the frequency of COVID-19 infection in patients using omalizumab was 10% insert ignore into journalissuearticles values(n=2);. With the pandemic, while our patients’ working-study habits were affected negatively insert ignore into journalissuearticles values(n=10, 50%);, their appetite increased insert ignore into journalissuearticles values(n=8, 40%);, and it was noted that there have been changes in their sleep patterns insert ignore into journalissuearticles values(n=8, 40%);. Conclusion: The COVID-19 pandemic has significantly affected our patients’ treatments and follow-ups. Our results support the argument that the use of omalizumab does not increase the risk of SARS-CoV-2 infection.
Keywords : Astım, COVİD 19, Ürtiker, omalizumab

ORIGINAL ARTICLE URL